Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
Crossref DOI link: https://doi.org/10.1007/s00262-016-1865-y
Published Online: 2016-08-01
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sand, Kristoffer http://orcid.org/0000-0002-7926-9867
Theorell, Jakob
Bruserud, Øystein
Bryceson, Yenan T.
Kittang, Astrid Olsnes
Funding for this research was provided by:
Helse Vest (NO)
Kreftforeningen (NO)
Universitetet i Bergen (NO)
License valid from 2016-08-01